GeoVax to Participate in Upcoming December Investor Events
29 Novembro 2023 - 11:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced that its
senior management will participate in two upcoming investor events:
NobleCon19, December 3-5, 2023, Boca Raton,
FLDate/Time: December 4, 2023 at
10:00 a.m. ETPresentation
Topic: Corporate Overview and
UpdateSpeaker: David Dodd, Chairman
& CEO
Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity
Conference will be held at Florida Atlantic University, Executive
Education Complex, in Boca Raton, FL. There will be an opportunity
to meet GeoVax’s management during a breakout session scheduled
immediately following the Company’s presentation.
A video webcast of the presentation will be available the
following day on GeoVax’s website (www.geovax.com) and as part of a
complete catalog of presentations available at Noble Capital
Markets’ Conference website (www.nobleconference.com) and on
Channelchek (www.channelchek.com) the investor portal created by
Noble. The webcast will be archived for 90 days on each platform
following the event.
Emerging Growth Conference, December 6-7, 2023,
VirtualDate/Time: December 6, 2023
at 3:25 p.m. ETPresentation
Topic: Update on Next-Generation COVID-19
Vaccine ProgramSpeaker: David Dodd,
Chairman & CEO
For more information and to register to attend the GeoVax
presentation, please visit Emerging Growth Conference.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in three Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a primary vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient, and as a booster vaccine in patients
with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is
in a Phase 2 clinical trial evaluating the vaccine as a more
robust, durable COVID-19 booster among healthy patients who
previously received the mRNA vaccines. GeoVax has a leadership team
who have driven significant value creation across multiple life
science companies over the past several decades. For more
information, visit our website: www.geovax.com.
Company Contact: |
|
Investor Relations Contact: |
|
Media Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
|
|
|
|
|
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024